VolitionRx downgraded to Hold at Benchmark on valuation

Benchmark analyst Bruce Jackson downgraded VolitionRx to Hold from Buy with no price target. VolitionRx announced a "string of positive news" for its Nu.Q vet business and continues to move forward with development of its human test for netosis, but even if the firm were to assume 2025 revenue north of $50M, a price target of $2.90 it would derive from that "would represent modest upside to the current price considering the duration risk," prompting it to lower its rating based on the stock’s current valuation.